Patents by Inventor Julien Mamet

Julien Mamet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200405742
    Abstract: The present disclosure relates to method of treating or preventing pain in a patient having a high pain catastrophizing scale (PCS) score, comprising administering an oligonucleotide inhibitor of a transcription factor to said patient.
    Type: Application
    Filed: February 25, 2019
    Publication date: December 31, 2020
    Inventors: Donald C. MANNING, Scott HARRIS, Kimberly HEBERT, Dina GONZALEZ, Julien MAMET, William MARTIN, Rick ORR
  • Patent number: 10683502
    Abstract: Provided are therapeutic agents such as double-stranded nucleic acids, termed oligonucleotide decoys, pharmaceutical compositions comprising the same, and related methods of modulating nociceptive signaling, for instance, to prevent and/or treat pain.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: June 16, 2020
    Assignee: ADYNXX SUB, INC.
    Inventors: Julien Mamet, Rick Orr, Donald C. Manning, Scott Harris, William Martin
  • Publication number: 20200017853
    Abstract: The present disclosure relates to oligonucleotide decoys, pharmaceutical compositions thereof, and the use of such to modulate nociceptive signaling and to prevent and/or treat pain.
    Type: Application
    Filed: February 28, 2017
    Publication date: January 16, 2020
    Inventors: Donald C. Manning, Scott Harris, Kimberly Hebert, Dina Gonzalez, Julien Mamet, William Martin, Rick Orr
  • Publication number: 20190374644
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Application
    Filed: August 27, 2019
    Publication date: December 12, 2019
    Inventors: Julien MAMET, Scott HARRIS, George MILJANICH, Rick ORR, William K. SCHMIDT, Tony YAKSH, David C. YEOMANS
  • Patent number: 10434178
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: October 8, 2019
    Assignee: Adynxx Sub, Inc.
    Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K. Schmidt, Tony Yaksh, David C. Yeomans
  • Publication number: 20190276825
    Abstract: Provided are therapeutic agents such as double-stranded nucleic acids, termed oligonucleotide decoys, pharmaceutical compositions comprising the same, and related methods of modulating nociceptive signaling, for instance, to prevent and/or treat pain.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 12, 2019
    Inventors: Julien MAMET, Rick ORR, Donald C. MANNING, Scott HARRIS, William MARTIN
  • Patent number: 10287583
    Abstract: Provided are therapeutic agents such as double-stranded nucleic acids, termed oligonucleotide decoys, pharmaceutical compositions comprising the same, and related methods of modulating nociceptive signaling, for instance, to prevent and/or treat pain.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 14, 2019
    Assignee: Adynxx, Inc.
    Inventors: Julien Mamet, Rick Orr, Don Manning, Scott Harris, William Martin
  • Patent number: 10041069
    Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: August 7, 2018
    Assignee: Adynxx, Inc.
    Inventor: Julien Mamet
  • Publication number: 20180015165
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Application
    Filed: April 5, 2017
    Publication date: January 18, 2018
    Applicant: Adynxx, Inc.
    Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K. Schmidt, Tony Yaksh, David C. Yeomans
  • Publication number: 20170247694
    Abstract: Provided are therapeutic agents such as double-stranded nucleic acids, termed oligonucleotide decoys, pharmaceutical compositions comprising the same, and related methods of modulating nociceptive signaling, for instance, to prevent and/or treat pain.
    Type: Application
    Filed: August 14, 2015
    Publication date: August 31, 2017
    Inventors: Julien Mamet, Rick Orr, Don Manning, Scott Harris, William Martin
  • Patent number: 9700624
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: July 11, 2017
    Assignee: Adynxx, Inc.
    Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K Schmidt, Tony Yaksh, David C Yeomans
  • Publication number: 20160222382
    Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
    Type: Application
    Filed: February 9, 2016
    Publication date: August 4, 2016
    Inventor: Julien Mamet
  • Patent number: 9290762
    Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: March 22, 2016
    Assignee: Adynxx, Inc.
    Inventor: Julien Mamet
  • Publication number: 20150111956
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Application
    Filed: May 9, 2013
    Publication date: April 23, 2015
    Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K Schmidt, Tony Yakash, David C Yeomans
  • Publication number: 20140343132
    Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
    Type: Application
    Filed: April 22, 2014
    Publication date: November 20, 2014
    Applicant: Adynxx, Inc.
    Inventor: Julien Mamet
  • Patent number: 8741864
    Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: June 3, 2014
    Assignee: Adynxx, Inc
    Inventor: Julien Mamet
  • Publication number: 20120232131
    Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
    Type: Application
    Filed: December 9, 2011
    Publication date: September 13, 2012
    Applicant: ADYNXX, INC.
    Inventor: Julien MAMET
  • Patent number: 8093225
    Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: January 10, 2012
    Assignee: Adynxx, Inc.
    Inventor: Julien Mamet
  • Publication number: 20110166212
    Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
    Type: Application
    Filed: March 15, 2011
    Publication date: July 7, 2011
    Applicant: ADYNXX, INC.
    Inventor: Julien MAMET
  • Patent number: 7943591
    Abstract: The present invention relates to double-stranded oligonucleotides, pharmaceutical compositions thereof, and use of such double-stranded oligonucleotides and pharmaceutical compositions to modulate nociceptive signaling in a cell or prevent and/or treat pain in a patient.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: May 17, 2011
    Assignee: Adynxx, Inc.
    Inventor: Julien Mamet